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Abstract
The tumor suppressor p53 is known to be able to trigger apoptosis in response to DNA damage, oncogene activation, and
certain chemotherapeutic drugs. In addition to its transcriptional activation, a fraction of p53 translocates to mitochondria
at the very early stage of apoptosis, which eventually contributes to the loss of mitochondrial membrane potential,
generation of reactive oxygen species (ROS), cytochrome c release, and caspase activation. However, the mitochondrial
events that affect p53 translocation are still unclear. Since mitochondrial uncoupling has been suggested to contribute to
cancer development, herein, we studied whether p53 mitochondrial translocation and subsequent apoptosis were affected
by mitochondrial uncoupling using chemical protonophores, and further verified the results using a siRNA approach in
murine skin epidermal JB6 cells. Our results showed that mitochondrial uncoupling blocked p53 mitochondrial translocation
induced by 12-O-tetradecanoylphorbol 13-acetate (TPA), a known tumor promoter to induce p53-mediated apoptosis in
skin carcinogenesis. This blocking effect, in turn, led to preservation of mitochondrial functions, and eventually suppression
of caspase activity and apoptosis. Moreover, uncoupling protein 2 (UCP2), a potential suppressor of ROS in mitochondria, is
important for TPA-induced cell transformation in JB6 cells. UCP2 knock down cells showed enhanced p53 mitochondrial
translocation, and were less prone to form colonies in soft agar after TPA treatment. Altogether, our data suggest that
mitochondrial uncoupling may serve as an important regulator of p53 mitochondrial translocation and p53-mediated
apoptosis during early tumor promotion. Therefore, targeting mitochondrial uncoupling may be considered as a novel
treatment strategy for cancer.
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Introduction
Most of the cell’s redox reactions take place in mitochondria,
which supply cellular energy by oxidating the major products of
glucose, pyruvate, and NADH. Substrate oxidation in this cellular
respiration process generates a proton gradient across the
mitochondrial inner membrane that establishes the electrochem-
ical potential (Dym). The energy contained in Dym is mainly used
for ATP synthesis (oxidative phosphorylation). However, not all of
the energy available in the electrochemical gradient is coupled to
ATP synthesis. Some of the energy is consumed by ‘‘proton leak’’
reactions, by which protons pumped out of the matrix are able to
reflow back along the proton gradient through proton conduc-
tance pathways in the inner membrane that bypass the ATP
synthase. As a result, the energy derived from the metabolic
oxidation reaction is dissipated as heat [1–4]. The nonproductive
proton leak termed mitochondrial uncoupling is physiologically
important and accounts for 20–25% of basal metabolic rate [5,6].
Notably, the impact of mitochondrial uncoupling on cellular
physiology is not restricted to normal cells. Mitochondrial
uncoupling also plays an important role in the reprogramming
of cancer cell metabolism [7]. ROS generation is involved in the
regulation of many physiological processes in cancer cells which
promotes further genomic instability; and upregulates signaling
pathways of cellular growth and proliferation. However, if
produced excessively, ROS may also be harmful to the cell by
initiating cell death pathways [8,9]. Hence, a well controlled ROS
level in cancer cells is of critical importance for tumor cell
physiology, growth and survival [10]. Since mitochondrial
uncoupling has been suggested to have a natural antioxidant
effect that increases respiratory rates and thus attenuates ROS
generation [11–13], it is not surprising that high levels of
mitochondrial uncoupling are found in various chemoresistant
cancer cell lines, which may provide a prosurvival advantage to
tumor cells [14,15].
p53, considered as a pivotal tumor suppressor, can initiate
apoptosis in response to cellular stress stimuli (e.g. drugs,
irradiation, UV, hypoxia) and the expression of viral or cellular
oncogenes [16]. In addition, mutations of p53 are found in more
than 50% of all human cancers [17]. Interestingly, recent studies
have suggested that p53 and mitochondrial uncoupling are
contradictory during apoptosis. It was reported that the Warburg
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associated with UCP2 activation, and dissipation of Dym by
protonophore carbonyl cyanide 3-chlorophenylhydrazone (CCCP)
opposes the onset of apoptosis [18]. Furthermore, overexpression
of UCP2 in several colon cancer cell lines is able to promote
chemoresistance which is, at least in part, resulting from the
inhibition of p53-induced apoptosis by posttranslational modifica-
tion of p53 [19]. These data suggests a strong relationship between
mitochondrial uncoupling and the p53-mediated apoptotic
pathway in the tumor metabolism network.
Our previous studies using the skin carcinogenesis model
revealed that during early tumor promotion, the tumor suppressor
p53 was activated after tumor promoter treatment, and a fraction
of p53 translocated into mitochondria which preceded its nuclear
translocation. Moreover, the mitochondrial p53 targeted the
primary antioxidant defense enzyme, manganese superoxide
dismutase (MnSOD), leading to suppression of its superoxide
scavenging activity, as well as, increases in ROS levels [20–23].
Thus, in addition to the direct apoptotic activity of mitochondrial
p53, the ability to induce ROS accumulation might serve as a
positive feed-back loop and play an essential role in the p53-
mediated apoptosis pathway [24]. However, as a major contrib-
utor to cancer survival, whether mitochondrial uncoupling could
exert an anti-apoptotic influence on TPA-induced skin tumor
promotion, and the precise mechanisms by which mitochondrial
uncoupling may interact with p53 mitochondrial translocation and
associated cell apoptosis pathways are not known and have been
explored here.
Materials and Methods
Cell line, reagents, and treatment
Murine epidermal JB6 P+ (CL 41, promotable by TPA
treatment) cells were established and maintained as previously
described [25]. p53 is wild-type in this cell line [26]. The cells were
grown in Essential Modified Eagle’s Medium (EMEM) supple-
mented with 4% fetal bovine serum, 2 mM of L-glutamine,
50 mg/ml penicillin and 50 mg/ml streptomycin. Murine skin
keratinocyte 308 cells were growth in S-MEM medium supple-
mented with 8% Chelexed FBS, 2 mM of L-glutamine, 0.1 mM
nonessential amino acids, 50 mMC a
2+, and 50 mg/ml penicillin
and 50 mg/ml streptomycin. 308 cells carry mutated H-ras at
codon 61 but wild-type in p53 [23]. 20 mM carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP) and carbonyl cyanide
3-chlorophenylhydrazone (CCCP) (both were purchased from
Sigma, St. Louis, MO) stock solutions were prepared in
dimethylsulfoxide (DMSO). 12-O-tetradecanoylphorbol 13-acetate
(TPA, purchased from Sigma) was prepared as 1 mM stock
solution in DMSO. All of the stock solutions were diluted directly
in the cell culture medium, and the final concentrations of FCCP,
CCCP, and TPA used were 10 mM, 5 mM, and 100 ng/ml,
respectively. For all of the pretreatment studies, the reagents were
removed before TPA treatment.
Cell transfection and gene knockdown
A combined pool of 3 target-specific siRNAs and specific siRNA
transfection reagent (Santa Cruz) were used to inhibit UCP2
expression. For p53 knock down experiments, pBabe-U6 plasmids
encoding shRNA that specifically inhibit p53 expression [27] were
used together with FuGENE HD transfection reagent (Roche).
Healthy and subconfluent JB6 P+ cells were transfected for 48 h
before further analysis. A fluorescein conjugated non-targeting
siRNA (Santa Cruz) and a GFP-encoding control plasmid was
used to monitor the transfection efficiency. The expression of
target genes was further examined by Western blot analysis with
specific antibodies.
Detection of mitochondrial membrane potential
Five thousand JB6 cells were seeded in 96-well plates with 150-
ml medium. Twenty-four hours after plating, cells were treated as
indicated. After washing with PBS, cells were incubated in fresh
medium containing 2 mg/ml of 5,59,6,69-tetrachloro-1,19,3,39-
tetraethylbenzimidazol-carbocyanine iodide (JC-1, Molecular
Probes, Eugene, Oregon) for 30 min. The dye was then removed;
and cells were washed with PBS. Fluorescence intensity was
measured immediately using fluorescence spectrometry (Synergy
HT, BioTek, Winooski, VT). For JC-1 green, Ex=485, Em=528;
for JC-1 red, Ex=530, Em=590. The fluorescence signals from
the cells only (no JC-1 dye added) were used to subtract the sample
values from each corresponding well. The ratio of the red to green
fluorescence of JC-1 was calculated. Experiments were repeated
for three times and at the least triplicate samples were included in
each experiment.
Detection of mitochondrial ROS generation
The mitochondrial levels of ROS were assayed using the
mitoSOX Red dye. Briefly, five thousand JB6 P+ cells were seeded
in a 96-well plate and incubated overnight. Twenty-four hours
after plating, cells were treated as indicated in each experiment.
After washing with warm PBS, cells were incubated with fresh
medium containing 5 mM mitoSOX Red (Molecular Probes,
Eugene, OR) for 15 min at 37uC. The fluorescence intensity was
measured at excitation/emission of 530/590 nm using fluores-
cence spectrometry (Synergy HT,). The cells only sample (no
mitoSOX dye added) was used as the background. Experiments
were repeated for three times and at least triplicate samples were
included in each experiment.
Immunofluorescent staining of p53
Ten thousand JB6 or 308 cells were seeded in eight-well Lab-Tek
chamber slides w/cover (Nalge Nunc International, Naperville, IL)
in 400 ml medium per well and incubated overnight. Twenty-four
hours after plating, cells were incubated with 200 nM of
MitoTracker Red CMX-Ros (Molecular Probes) in culture medium
for 30 min. Afterwards the dye was removed, and cells were treated
as indicated. The cells were washed and fixed in 4% formaldehyde
solution for 15 min at room temperature. After rinsing with cold
PBS, cells were permeabilized with 0.5% Triton X-100 for 10 min
at room temperature. After blocking, an anti-p53 antibody (Ab-11,
Calbiochem) was added (1:64 dilution) and incubated at 37uC for
1 hour followed by incubation with an anti-mouse IgG-FITC
(Sigma, 1:128 dilution) for 1 hour. After removal of antibodies, the
cells were rinsed with PBS and mounted with 90% glycerol.
Fluorescence was immediately observed using a wide-field inverted
microscope (Nikon Eclipse TE300).
Isolation of mitochondrial fraction from JB6 and 308 cells
After treatment, cells were suspended in 2 ml mitochondria
isolation buffer [0.225 M mannitol, 0.075 M sucrose, 1 mM
EGTA (pH adjusted to 7.4 with 0.5 M Tris)] in a 10-ml Wheaton
homogenizer tube and carefully homogenized for 30 strokes on
ice. The cell debris was removed by centrifugation at 2,500 rpm
(,6006g) twice for 5 min. The supernatant was filtered through a
nylon screen cloth (Small Parts, Inc., Miami Lakes, FL) and then
centrifuged at 10,000 rpm (,9,0006g) for 10 min. The superna-
tant was kept as the cytosolic fraction and the pellet was washed by
adding 0.5 ml of mitochondria isolation buffer and centrifuged at
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mitochondrial pellet was resuspended in 50–100 ml of mitochon-
dria isolation buffer containing protease inhibitor cocktail
(Research Products International Corp. Mount Prospect, IL).
The purity of the mitochondrial and cytosolic fractions was further
examined by Western blot analysis.
Mitochondrial Complex I activity assay
Complex I specific activities were measured as described by Birch-
Machin et al. [28] with slight modifications [29]. Mitochondrial
samples isolated from JB6 cells were subjected to three fast freeze-thaw
cycles in hypotonic buffer. The protein concentration was measured
and adjusted to 1.33 mg/ml before the assay. The assay mixtures,
which contained 25 mM potassium phosphate buffer (pH 7.2), 5 mM
MgCl2,2m MK C N ,2 . 5m g / m lb o v i n es e rum albumin (fraction V),
0.13 mM NADH, 65 mM coenzyme Q1, and 2 mg/ml antimycin A,
were incubated at 30uC for 1 min. Mitochondria were added to
initiate the reaction, and the initial rate of NADH oxidation was
monitored at 340 nm for 1 min (DA). The reaction was inhibited by
2 ml of 2 mg/ml rotenone and the rate of NADH oxidation was
monitored for 1 min (DAr). The relative complex activity was
calculated according to the following formula: DA-DAr.
Western blot analysis
Total cell lysate was prepared by sonicating cells in RIPA buffer
supplemented with protease inhibitor cocktail for 10 s. Mitochondrial
fractions were prepared as described above and 0.5% Triton X-100
was added to the final solutions. Protein samples were separated on a
10% or 15% SDS-PAGE gel. The following antibodies were used:
anti-p53 (Ab11, Calbiochem), anti-MDM2 (Ab2, Calbiochem), anti-
Bax (P19, Santa Cruz), anti-cytochrome c (A8, Santa Cruz), and anti-
active caspase-3 (AB3623, Chemicon). For loading controls, antibod-
ies against Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(6C5) and succinate dehydrogenase complex subunit B (SDHB)
(FL280) were used (both purchased from Santa Cruz).
Caspase 3 Activity assay
Total cell lysate was prepared and caspase 3 activities were
detected using CasPASE apoptosis assay kit (G-Biosciences, St
Louis, MO) following the manufacturer’s instructions.
Nucleosome fragmentation assay
Cellular fragmentation was performed following the manufac-
turer’s instructions. DNA fragmentation in cell lysate was detected
using Cell Death Detection ELISA (Roche, Indianapolis, IN). This
method applies an anti-histone antibody to capture the histone-
DNA fragments, then applies a HRP-labeled anti-DNA antibody
to detect fragmented DNA.
Soft agar assay
Soft agar assay was performed as described by Colburn et al.
[30] with slight modifications. 0.5% Agar mix (40 ml melted
1.25% agar solution, 40 ml 26EMEM, 10 ml FBS, 10 ml PBS,
1 ml glutamine, 50 ml penicillin & streptomycin) was prepared and
kept in a 50uC water bath. Bottom agar was prepared by adding
desired treatments (e.g. 6.66 ng/ml TPA) to the 0.5% agar mix.
Top agar was prepared by diluting 1 fraction of 1610
5 cells/ml
single cell suspension with 2 fractions of 0.5% agar mix and
desired treatments. 2.5 ml of bottom agar and 0.75 ml of top agar
was laid into each well of the 6-well plates. Cells were incubated in
a humidified 37uC, 5% CO2 incubator for 2 weeks. Cells were
then stained with 0.25 mg/ml neutral red overnight, and the
number of colonies were counted and plotted.
Statistical analysis
Statistical analysis was performed using one-way ANOVA
followed by Newman-keuls post-test. Data are reported as means
6 standard error (S.E.M.). p,0.05 was considered significant.
Results
TPA induced p53 mitochondrial translocation,
mitochondrial dysfunction and apoptosis in JB6 P+ cells
Initially, a time course study was performed to detect p53
accumulation in the whole cell lysate. The increase in p53
protein levels was observed as early as 1 h after 100 nM TPA
treatment and remained at high levels for the duration of the
24 h treatment (Fig. 1A). As a major p53 transcriptional target
protein, MDM2 showed a rapid response with a significant
increase at 1 h, a slight decline at 3 h, and increased again at
later time points after the TPA treatment (Fig. 1A). Our previous
studies have revealed that a fraction of p53 translocated to
mitochondria during TPA-induced tumor promotion [22].
Herein, we performed a detailed time course study. After
treatment, cells were subjected to a fragmentation procedure by
which mitochondrial and cytosolic fractions were collected and
qualified with specific protein markers. In the mitochondrial
fractions, PCNA, a nuclear marker, was undetectable (Fig. 1B);
GAPDH has been reported to localize in mitochondria [31].
Our study showed a rapid mitochondrial p53 increase at 1 h that
remained throughout the 24-h time course post TPA treatment
(Fig. 1A, lower panel). Consistent with the p53 mitochondrial
translocation, correspondent changes in mitochondrial functions
were also observed, which included increased ROS generation,
loss of mitochondrial complex I activity, decreased mitochon-
drial membrane potential, and release of intermembrane
cytochrome c (Fig. 1C,1F). Moreover, the activation of p53
was associated with increases in the expression levels of Bax, a
pro-apoptotic Bcl-2 protein which can trigger the MOM
permeabilization in cancer cell apoptosis [32], as well as,
increases in DNA fragmentation (Fig. 1G&1H).
To further confirm the correlation between p53 activation and
downstream responses including mitochondrial dysfunction and
apoptosis, a designed p53-targeted shRNA sequence-containing
plasmid was introduced into JB6 P+ cells. In transfected cells, p53
expression was significantly inhibited, and TPA-induced p53
accumulation and mitochondrial translocation were suppressed
(Fig. 1I). As expected, p53 knock down cells did not respond to
TPA treatment in both mitochondrial functions (Fig. 1C–1F) and
apoptotic cell death (Fig. 1G&1H). These results showed that
presence of p53 is critical for TPA-induced mitochondrial
dysfunction and apoptosis in JB6 P+ cells.
Mitochondrial uncoupling suppressed TPA-induced p53
mitochondrial translocation in JB6 P+ cells
The above studies show that the tumor promoter TPA induces
p53 mitochondrial translocation and subsequent mitochondrial
dysfunction. Next, we examined whether mitochondrial uncou-
pling, in turn, affected p53 mitochondrial translocation and
subsequent apoptosis. Indeed, immunofluorescent staining studies
demonstrated that TPA-induced p53 mitochondrial translocation
was extensively blocked by the protonophore FCCP, which is
known to be able to uncouple oxidative phosphorylation by
carrying protons across the mitochondrial membrane. As shown in
Figure 2A, 30 min after TPA treatment, a fraction of p53 (green
signal) was detected in the mitochondria which colocalized with
the mitochondrial marker-MitoTracker Red. This mitochondrial
accumulation of p53 was significantly reduced by FCCP co-
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blot analysis. The induced accumulation of p53 in mitochondria
was fully blocked by FCCP co-treatment at both 1 h and 6 h after
TPA treatment (Fig. 2B). Interestingly, in contrast to the effect of
FCCP in the mitochondria, there was no significant reduction in
TPA-induced cellular p53 accumulation and transcriptional
activation of MDM2 and Bax by FCCP co-treatment (Fig. 2C).
Taken together, the effect of mitochondrial uncoupling seems to
be specific for mitochondrial p53 accumulation and non-
transcriptional p53 activities. Another mitochondrial uncoupling
reagent, CCCP, also showed results similar to FCCP treatment.
CCCP co-treatment suppressed TPA-induced p53 mitochondrial
translocation with no dramatic effects on the whole cellular p53
levels (Fig. 2D).
Figure 1. TPA induced p53 mitochondrial translocation, mitochondrial dysfunction and apoptosis in JB6 P+ cells. WC: wild-type JB6
P+ cells treated with DMSO (control); WT: wild-type JB6 P+ cells treated with 100 nM TPA; KC: p53-knocdown JB6 P+ cells treated with DMSO
(control); KT: p53-knockdown JB6 P+ cells treated with 100 nM TPA; GAPDH or SDHB served as the loading control. (A) A time course study of TPA-
induced cellular and mitochondrial p53 accumulation, as well as, downstream MDM2 expression. (B) Qualification of mitochondrial fractions. (C) p53
knockdown and ROS levels. Cells were treated for 1 h. (D) p53 knockdown and mitochondrial complex I activities. Cells were treated for 1 h. (E) p53
knockdown and mitochondrial membrane potential. Cells were treated for 1 h. (F) p53 knockdown and cytochrome c release. Cells were treated for
6 h. (G) p53 knockdown and cellular Bax levels. Cells were treated for 6 h. (H) p53 knockdown and cell death levels revealed by DNA fragmentation
assays. Cells were treated for 6 h. (I) p53 mitochondrial translocation verified by gene knockdown assays. *: significant difference compared to WC; **:
significant difference compared to WT.
doi:10.1371/journal.pone.0013459.g001
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mitochondrial translocation in 308 cells
Our previous studies have demonstrated that TPA can induce
p53 activation and mitochondrial translocation in 308 cells [23].
Here we examined whether mitochondrial uncoupling also affects
p53 mitochondrial translocation and subsequent apoptosis in this
cell model. As shown in Fig. 3A, similar to the results in JB6 cells,
TPA treatment induced rapid (30 min after TPA treatment)
Figure 2. Mitochondrial uncoupling suppressed TPA-induced p53 mitochondrial translocation in JB6 P+ cells. (A) Immunofluorescent
staining of p53 at 30 min after TPA treatment. First panel: p53 detected with an anti-p53 antibody. Second panel: mitochondria labeled with
MitoTracker Red. Third panel: overlay pictures. (B) p53 mitochondrial translocation. SDHB served as the loading control. (C) Cellular p53 activation and
downstream gene expression. GAPDH served as the loading control. FCCP: 10 mM. (D) Western blot analysis of the mitochondrial (left) and the whole
cellular (right) p53 levels after CCCP treatment. CCCP: 5 mM.
doi:10.1371/journal.pone.0013459.g002
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rescent staining studies, and this p53 translocation was blocked by
FCCP co-treatment. These results were further confirmed using
Western blot analysis. The mitochondrial p53 levels were
suppressed by FCCP co-treatment 6 h after TPA treatment
(Fig. 3B). Not surprisingly, TPA-induced apoptotic cell death was
also suppressed by FCCP cotreatment (Fig. 3C).
Mitochondrial uncoupling prevented mitochondrial
dysfunction and apoptosis associated with p53
mitochondrial translocation in JB6 P+ cells
Given the strong correlation between p53 and downstream
apoptotic events, we further examined whether blocking p53
mitochondrial translocation by mitochondrial uncoupling affected
mitochondrialfunctions andapoptosis.Asshown inFigure4,FCCP
alone caused a strong decrease in mitochondrial membrane
potential; whereas, no obvious effects on the ROS level, Complex
I activity and cytochrome c levels were observed. However, FCCP
co-treatmentsignificantlyattenuated orblocked TPA-induced rapid
ROS generation (Fig. 4A), the loss of Complex I activity (Fig. 4B),
and mitochondrial cytochrome c release (Fig. 4D). Although the
effect of FCCP on TPA-induced decrease in mitochondrial
membrane potential was unable to be detected because of the
extensive dissipating effect of FCCP alone (Fig. 4C), our current
data still indicates that mitochondrial uncoupling exerts an efficient
inhibiting effect on p53-associated mitochondrial dysfunction.
Figure 3. Mitochondrial uncoupling suppressed TPA-induced p53 mitochondrial translocation in 308 cells. (A) Immunofluorescent
stainingof p53 at30 minafterTPAtreatment.Firstpanel:p53 detectedwith ananti-p53antibody.Secondpanel:mitochondrialabeledwith MitoTracker
Red. Third panel: overlay pictures. (B) p53 mitochondrial translocation. SDHB served as the loading control. (C) Apoptotic cell death revealed by the DNA
fragmentation ELISA assay. *: Significant difference compared to the control. **: Significant difference compared to TPA treatment.
doi:10.1371/journal.pone.0013459.g003
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translocation in JB6 P+ cells. (A) ROS levels. (B) Mitochondrial complex I activities. (C) Mitochondrial membrane potential. (D) Cytochrome c
detected in both mitochondrial and cytosolic fractions. GAPDH or SDHB served as the loading control. (E) Cell death levels revealed by the DNA
fragmentation ELISA assay. (F) Apoptosis revealed by detection of cleave caspase 3 and caspase 3 activity assay. *: Significant difference compared to
the control. **: Significant difference compared to TPA treatment.
doi:10.1371/journal.pone.0013459.g004
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integrity by mitochondrial uncoupling, TPA-induced apoptosis was
also attenuated by FCCP co-treatment as detected using the Cell
Death ELISA and cleaved caspase 3 activity assay (Fig. 4E, 4F).
UCP2-knockdown JB6 P+ cells showed enhanced p53
mitochondrial translocation and decreased anchorage-
independent growth in response to TPA treatment
It is notable that a mild uncoupling effect is present in most
mammal cells. Ample evidence has indicated that this mild
uncoupling has multiple physiological roles including export of fatty
acid anions from mitochondria, regulation of insulin secretion, as well
as, attenuation of mitochondrial superoxide production [33]. There
are a series of specific uncoupling proteins (UCP1–5) in mammal
cells. Among which, UCP2 is widely distributed in various tissues and
critical for ROS regulation, as well as, survival of tumor cells [19,33].
Given these facts, we further examined the role of UCP2 in TPA-
induced p53 mitochondrial translocation and cell transformation of
JB6 P+ cells. UCP2 gene expression was knocked down using a
specific siRNA transfection approach (Fig. 5A). As shown in Fig. 5B,
UCP2 absence induced a small amount of p53 mitochondrial
translocation, and also enhanced TPA-induced p53 mitochondrial
translocation. Moreover, the soft agar (cell transformation) assay
demonstrated a highly dependence on the presence of UCP2, since
the UCP2-knockdown cells were much less prone to form colonies
compared to the control JB6 P+ cells (Fig. 5C,5D). These data
indicated that UCP2-mediated mitochondrial uncoupling may
contribute to TPA-induced tumor transformation of JB6 P+ cells.
Discussion
Our previous studies have demonstrated that during early skin
carcinogenesis, increased apoptotic cell death is associated with
increased cell proliferation [20]. As an important apoptotic signal,
the tumor suppressor p53 was activated as indicated by increased
expression levels, DNA binding activity, expression of its target
genes, and moreover, translocation to mitochondria [20,22].
Potentially, as a defending mechanism against carcinogenesis, p53
induces apoptosis via transcription-dependent and transcription-
independent pathways, two fundamentally different, but synergis-
tic mechanisms of action [16,34,35]. In the nucleus, p53 regulates
the transcription of proapoptotic effectors such as Bax, Puma and
Noxa. Meanwhile, a fraction of p53 translocates to mitochondria
where it directly interacts with mitochondrial proapoptotic
proteins such as p53AIPI [36] and multi-domain members of
the Bcl2 family [37], as well as, the antioxidant defense enzyme,
manganese superoxide dismutase [22].
Mitochondria are the power house of the cell, and ATP is
generated through the mitochondrial electron transport chain.
How p53 affects major mitochondrial respiration has not been well
studied. On the other hand, changes in mitochondrial functions
will likely modulate p53 mitochondrial translocation as well. Our
previous studies have suggested that the mitochondrial perme-
ability transition pore (PTP) could serve as both the cause and
barrier for p53 mitochondrial translocation, since mitochondrial
accumulation of p53 induces PTP opening; whereas blocking the
PTP by cyclosporine A suppresses p53 translocation to mitochon-
dria [38]. Our current study aims to investigate if the
mitochondrial electron transport chain is uncoupled during early
cancer development, and whether mitochondrial uncoupling
affects p53 translocation to mitochondria. Our results suggest that
chemically uncoupling oxidative phosphorylation in mitochondria
is able to block p53 mitochondrial translocation; and, in turn,
antagonize most of the apoptotic downstream events including
rapid ROS generation, mitochondrial cytochrome c release, loss of
mitochondrial Complex I activity, and finally apoptosis.
Figure 5. UCP2 knockdown enhanced p53 mitochondrial translocation and decreased colony formation in response to TPA
treatment. (A) UCP2 knockdown efficiency examined by Western blot analysis. (B) p53 mitochondrial translocation. (C) Soft agar colony formation
assays of JB6 P+ cells (light micrograph: 1006 magnification). (D) Quantification of formed colonies. Cells grown in 0.33% soft agar containing
6.66 ng/ml TPA or vehicle (DMSO 10006 diluted). *: Significant difference compared to DMSO treatment. **: Significant difference compared to
normal cells with TPA treatment.
doi:10.1371/journal.pone.0013459.g005
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drial uncoupling in anti-cancer therapy. It is well known that
cancer cells have acquired a metabolic reprogramming to
fermentation which can bypass the Pasteur Effect (the Warburg
Effect) [39]. Recently, this kind of ‘‘respiratory defect’’ is
associated with mitochondrial uncoupling [7] based on the facts
that UCP2, one of the major uncoupling proteins in mammals, is
overexpressed in various chemoresistant cancer cell lines and
primary human cancer samples; and that overexpression of UCP2
leads to an increased apoptotic threshold [19]. Moreover,
mitochondrial uncoupling is reported to be able to oppose the
onset of apoptosis in several human cancer cell lines [18,19,40].
Our results suggest that the contribution of UCP2 in cancer cells
might be more complicated than described before. In our studies,
the UCP2 knockdown cells show a stronger response to TPA-
induced p53 mitochondrial translocation than the control cells by
being less prone to form colonies in response to TPA treatment in
the soft agar assay. These results suggest that UCP2 may play an
important role in both transformed and transforming cells. The
overexpression of UCP2 in cancer cells may be a result of a long-
term selecting procedure during transformation, since any mutant
that results in UCP2 upregulation could help cells escape from
apoptosis mastered via the p53 network. Given the fact that
mitochondrial uncoupling could cause dissipation of the mito-
chondrial potential, a decrease of mitochondrial ROS generation,
and the sensitivity of p53 activation to the intrinsic redox balance
[33,19,24], it is reasonable to hypothesize that mitochondrial
uncoupling may provide malignant cells with a prosurvival
advantage by interfering with the p53-mediated apoptosis
pathway.
The present investigation suggests yet another relationship
between mitochondrial uncoupling, p53 mitochondrial transloca-
tion, and p53-induced apoptosis during early skin tumor
promotion in JB6 P+ and 308 cells. Our data demonstrated that
mitochondrial uncoupling efficiently prevented TPA-induced
mitochondrial ROS generation, and blocked p53 mitochondrial
translocation, leading to prevention of mitochondrial dysfunction
and attenuation of apoptotic cell death. Taken together, our
studies suggest a novel mechanism to explain why mitochondrial
uncoupling, as a major physiologic phenomenon during carcino-
genesis, may contribute to the viability and chemoresistance of
tumor cells; which is mediated at least in part, by converting a
mitochondrial physiological condition into a unique status. Thus,
mitochondrial uncoupling maintains ROS at a reasonable level
and interrupts the p53-ROS positive feed-back loop which further
prevents p53 mitochondrial translocation, associated mitochon-
drial dysfunction, and p53-mediated apoptosis.
In summary, our findings indicate that mitochondrial uncou-
pling modulates p53 mitochondrial translocation and associated
apoptosis pathways during skin tumor promotion. Therefore,
targeting mitochondrial uncoupling may be considered as a novel
treatment strategy for cancer.
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